According to curnt data, the capacity to caue nonprogrammed or un ule cell proliferation in tat tssues, a commo rc c of mica rcinonW my play a more important role i [40] [41] [42] [43] [44] [45] [46] (1996) Enormous progress has been made within the past several decades in assessing human cancer risk from chemical carcinogens. In fact, attempts to estimate risk potential have given rise to contradictions between Salmonella genotoxicity and rodent carcinogenicity with the existence of nongenotoxic (Ames-negative) carcinogens and genotoxic (Ames-positive) noncarcinogens (1) (2) (3) (4) (5) . The anomaly in question has provided us with a clue to interpretation of the relationship between genotoxicity and carcinogenicity. In terms of the cause of human carcinogenesis, the focus should now be placed on the role of nonprogrammed cell proliferation caused by exogenous agents rather than on their genotoxicity (6) (7) (8) (9) .
Preston-Martin et al. (10) claimed that human cancers are reflections of sustained cell proliferation caused by cell proliferative factors (consisting of chemical agents, hormones, etc.) becau4e nondividing cells in adults such as nerve cells and cardiomyocytes never develop tumors. In addition, Croy (11) assumed that estimation of genotoxic effects alone does not provide an accurate assessment of cancer risk to humans from chemical exposure. At present, when newly developed chemicals give rise to Ames-positive events, they are almost always restricted from release into the human environment by government regulation. Ames-positive events however do not always equate with carcinogenic events. It is necessary therefore to detect carcinogenicity by examining each chemical's ability to stimulate cell proliferation.
More recently, Mason (12) and Okey et al. (13) reported that some polycyclic aromatic hydrocarbons, which are genotoxic carcinogens, have the capability to increase cell proliferation through dioxin-aromatic hydrocarbon (Ah) receptor ligand complexes. Data also suggest that cell proliferation increased by genotoxic carcinogens is closely related to the development of tumors. This is the basis for the studies presented in this paper, which question to what extent noncarcinogens, as well as nongenotoxic and genotoxic hepatocarcinogens, exert cell proliferative action on hepatocytes in vivo (14) (15) (16) . The results show that most of the hepatocarcinogens tested clearly accelerate hepatocyte division whereas the majority of noncarcinogens gave no such effect.
The data suggest that the capacity to cause cell proliferation is common to nongenotoxic and genotoxic carcinogens. The mechanisms underlying this proliferation remain unclear in many cases, but the role of cell division in carcinogenesis is certainly a key point in the development of tumors. This paper reviews issues regarding nongenotoxic carcinogens and genotoxic noncarcinogens and proposes an interpretation in terms of nonprogrammed cell proliferation.
Definition of Nongenotoxic Carcinogens
The status of nongenotoxicants and genotoxicants should be evaluated using the standard Ames test alone, including a liver S9 mix from rats, mice, or hamsters. There are two principal reasons for this: 1) the standard Ames test has hitherto supplied a large number of the screening data on existing noncarcinogens as well as carcinogens, which provides the highest value of overall concordance, compared to other established genotoxicity tests (1); and 2) the simply defined terminology facilitates a general understanding to scientists studying mutation, cancer, and other fields. According to the definition of nongenotoxic carcinogens, at least 30% of existing carcinogens can be assigned to this category (1-4).
Jackson et al. (17) reported that almost all putative nongenotoxic carcinogens can be shown to be genotoxic when tested with a combination of several genotoxicity tests. The combined test system, however, also includes tests to detect tumor-promoting agents that have cell proliferative capabilities. Therefore, the data lead to questions about whether nongenotoxic carcinogens examined are indeed genotoxic.
In addition, almost all nongenotoxic carcinogens are also believed to induce genotoxicity in Salmonella TA102 (18) , which is supersensitive to active oxygen production. Screening data obtained with TA102 have, however, been limited so far. Festing (19) (34, 36, 37) .
Although there is no clear evidence for an increase in cell proliferation through the PPAR receptor (37) , some proto-oncogenes promoting cell proliferation, e.g., fos and jun, are known to be activated (34, 38, 39) .
Our RDS data suggest that formation of PPAR-ligand complexes also leads to cell proliferation (Table 1) . Thus, steroidsuperfamily receptor-mediated cell proliferation can be considered to be principally involved in early development of hepatocyte RDS induction. In addition, ligands may simultaneously give rise to equivocal DNA modifications. Progression of both phenomena in the same cells may result in effective disruption of cell-cycle controls so that hepatocarcinomas eventually arise. Among these receptors, particular attention is now being paid to the Ah receptor because it can react with a wide range of nongenotoxic and genotoxic agents as a ligand and it principally regulates induction of CYPlAI to metabolically activate polycyclic aromatic hydrocarbons (13) .
Several growth factors are also known to increase cell proliferative events in specific cells in tissues (40) , but the relationship between the roles of growth factors and cell proliferation in carcinogenesis is extremely difficult to assess. With regard to hepatocyte cell proliferation, the action of hepatocyte growth factor (HGF) investigated by Nakamura and his co-workers (41, 42 ) must be considered: HGF secreted from liver and other organs in response to chemical injury is known to promote the division of hepatic parenchymal cells by means of paracrine/endocrine mechanisms; moreover, the nature of the HGF-binding receptor has also been identified as a met proto-oncogene product (43) . Other growth factors taken into the liver are epidermal growth factor and transforming growth factor-fl1. At present, there is no simple explanation of how growth factors act in combination to bring about complicated events in vivo.
Of several RDS-positive carcinogens listed in Table 1 , at least 13 samples are generally well known to be hepatotoxicants in rats and mice (13, 14) Hildebrand et al. (46) and Perera (47) have indicated that the term "tumor promoters" should be limited to the discussion of two-stage model systems in which tumor development is examined after the application of an initiating agent. The term "nongenotoxic carcinogen" should be used to designate an Ames-negative agent that is capable of causing the development of malignant tumors in 2-year bioassays when animals are exposed to that agent alone. Definite differences between nongenotoxic carcinogens and tumor promoters are not likely to be established; therefore, confusion in the application of terminology will remain.
Tumor promoters are often considered to be carcinogenic when they test positive in 2-year animal bioassays, which leads to the interpretation that tumor promoters are equal to nongenotoxic carcinogens.
These nongenotoxic carcinogens are someVolume 104, Number 1, January 1996 * Environmental Health PerspectivesReview* Non-ienotoxic carcinoqens and genotoxic noncarcinogens times defined in terms of their carcinogenic potency in a range of animal species, strains, sexes, tissues, or organs, in contrast to the more limited promoter case. Experimental data for nongenotoxic carcinogens tend to show that the two groups are equivalent in practice, and tumor promoters may cause cell proliferation that is tissue or organ specific in animals (48) . A representative nongenotoxic carcinogen, benzene, which is a rodent carcinogen as well as a human carcinogen, induces tumors in a wide range of animal species and strains in both sexes and in many tissues and organs (4) . It is questionable, therefore, whether all nongenotoxic carcinogens are simply tumor promoters.
The confusion in use of the terms "nongenotoxic" and "tumor promoters" principally occurs when the cause of human cancers is considered. Current understanding suggests that the capacity of chemicals to cause cell proliferation is more important than the initiating effects of the chemicals. As far as the occurrence of human cancers is concerned, it may not be necessary to make a strict distinction between nongenotoxic carcinogens and tumor promoters as responsible agents. In the experimental field, however, a strict discrimination is always needed for regulatory authorities to properly assess human cancer risk.
My hypothesis is that hepatocarcinogenicity is due to stimulation of cell proliferation and production of equivocal DNA modifications. While (Table 1) . Thus, oxidative DNA stress might lead to development of hepatocarcinogenesis in cooperation with cell proliferation.
Some of the nongenotoxic noncarcinogens examined also induced hepatocyte RDS events (Table 1) . Such false-positive RDS events might be due to a tumor-promoting action on hepatocytes in vivo. As indicated by Ledda-Columbano et al. (39) , differences between nongenotoxic hepatocarcinogen-induced and tumor promoterinduced or mitogen-induced cell proliferation might be distinguished by analyzing the nature of overexpression of proto-oncogenes during early hepatocyte RDS induction. This approach might similarly be important to distinguish nongenotoxic carcinogens from tumor promoters.
. A representative promoter without carcinogenic potency, 12-O-tetradecanoylphorbol-13-acetate (TPA) was found to be carcinogenic in a long-term study when it was repeatedly applied to the skin of BALB/c mice (57) . Proliferation of keratinocytes is known to be controlled by TGF-R1 (40) , and hepatocytes respond to HGF (41, 42 (58) (59) (60) .
The cells used in genotoxicity tests are far more susceptible to conversion of genotoxic events to fixed mutations than cells existing in tissues. The applied systems have a number of defects in other areas, e.g., overapplication of drug-metabolizing enzymes, overdoses, and a relative lack of a detoxication process in vitro. Application of new genotoxicity tests that use mammalian cells with functioning gap junctions and a normal complement of enzymes is thus needed to prevent false-positive data for genotoxic noncarcinogens in the future.
In this respect, Cunningham et al. (27) reported that, although 2,4-and 2,6-diaminotoluene analogs were equally genotoxic for the Ames test, only 2,4-diaminotoluene was hepatocarcinogenic and increased hepatocyte RDS induction (Table 1) . Therefore, they argued that induction of liver tumors is likely to require both genotoxic action and stimulative potential for cell proliferation.
In addition, Goldsworthy et al. (8) reported interesting data on hepatocyte lacl genotoxic events and hepatocyte proliferation in transgenic mice using two alkylating agents, N-dimethylnitrosamine as a representative hepatocarcinogen and methylmethane sulfonate as a nonhepatocarcinogen. Both chemicals are known to be positive in in vivo mouse hepatocyte unscheduled DNA synthesis tests (61) as well as in the three types of genotoxicity tests. The data showed that N-dimethylnitrosamine caused lacl genotoxic events and hepatocyte proliferation in hepatocytes in vivo, whereas methylmethane sulfonate induced neither.
These findings also provide us with evidence that hepatocytes in tissue in vivo need cell proliferation for genotoxic lesions to become fixed and carcinogenesis to result. Thus, determination of proliferative response is considered to be most appropriate to predict hepatocarcinogenicity.
Relationship between Cell Proliferation and Chemical Hepatocarcinogenesis
Nongenotoxic carcinogens and tumor promoters can also act to clonally expand spontaneously occurring, initiated cells. Although clonal expansion by both types of agents may be generally accepted as contributory to development of tumors, at present it is unlikely to be accepted as a theory of tumor development for the reasons described below. Ward et al. (62) reasoned that, if the rate of spontaneously occurring, initiated cells is similar for each specific tissue, then more spontaneous cancers should occur in larger organs. Liu et al. (63) reported that HGF inhibited proliferation in glutathione S-transferase placental form-positive rat hepatocytes (putative preneoplastic foci cells) induced by N-diethylnitrosamine, whereas it stimulated cell division in nonlesion areas. Moreover, Schulte-Hermann et al. (64) claimed that putative preneoplastic foci cells of rat livers exhibit approximately 10-fold higher rates of apoptosis than normal hepatocytes. These points must be taken into account in any explanation based on clonal expansion. With regard to carcinogenesis by genotoxic and nongenotoxic carcinogens, the theory of genetic instability, which involves disruption of growth arrest checkpoints, is now considered to be of great advantage to understanding mechanisms of action.
The following summary of how cell proliferation might act in carcinogenesis takes into account recent information. First of all, an imbalance of the deoxynucleotide pool occurs (65, 66) , stimulating dihydrofolate and DNA polymerase a, for example. In the first stage of cell proliferation, this imbalance might be triggered by some factors, such as steroid-superfamily receptor-ligand complexes or HGF-receptor-ligand complexes, as described above. Of these factors, some are known to contribute to overexpression of some proto-oncogenes, which leads to further progression of nonprogrammed cell proliferation (34) (35) (36) .
In the second stage, appreciation of the role of sustained cell proliferation in the carcinogenesis procegs requires a comprehensive understanding with regard to methylation status (67) (68) (69) . Namely, a chronically maintained high rate of cell division can give rise to an imbalance in normal DNA methylation levels involving 5-methylcytosine (67) (68) (69) (70) (77) . When pRB is phosphorylated at the G1/S border with active cyclin-dependent kinase (Cdk)-G1 cyclin complexes, its linked transcription factor (E2F) (78) is released, which activates genes relating to progression of cell proliferation. Thus, phosphorylation involving Cdk-G1 cyclin complexes is promoted by the products of proto-oncogenes (myc, ras, etc.) and is inhibited by products of tumorsuppressor genes (p15, p16, p27, etc.), thus controlling normal cell division by means of the actions of "brakes and accelerators." It has been argued that the mechanisms of normal cell division are disrupted in carcinoma cells (76) .
With regard to inductive RDS events, namely nonprogrammed cell proliferation induced by chemicals, I have proposed that the initiation step requires biological stimuli that may give rise to an imbalance in the normal DNA methylation status. There are a number of ways in which this might also trigger unscheduled RDS. Taya (76) claimed that cell division is also accelerated when tumor-suppressor gene products (e.g., p15, p16, p27) are directly inactivated by exogenous chemicals. The DNA methylation status is affected by any imbalance between DNA methyltransferase and its demethylase activities in target cells (69) . It needs to be clarified whether genotoxic or nongenotoxic carcinogens might induce elevated activity of either DNA methyltransferase or its demethylase. DNA methylation processes are known to require choline and methionine; by administering a diet deficient in both chemicals, hepatocarcinomas can be induced, indicating a role for hypomethylation of hepatocyte DNA (79) . An imbalance in the DNA methylation status may thus exert effects without the necessity of sustained cell proliferation.
Finally, hepatocarcinogenesis should be considered from the standpoint of two events that occur with the lesion progression process and increasing age in experimental animals. In 2-year animal bioassays, it appears that progressively more malignant clones are repeatedly created from background altered populations. Also, with increasing age, the normal function of tumor-suppressor genes tends to gradually and spontaneously disrupt various cell types. By means of both continuous processes, apoptosis-resistant, semi-abnormal hepatocytes, which can go through the first gate of the pathway to tumors with accumulated genetic instability, may be selected. Such genetic instability will contribute to stepwise disruption of oncogenes and some tumor-suppressor genes. When tumor-suppressor genes lose their normal function, apoptosis-resistant abnormal hepatocytes may be able to go through the next gates leading to malignancy. This hypothesis is based on the occurrence of apoptosis-resistant abnormal hepatocytes and is supported by the data of Roberts et al. (80) , who reported that the majority of the hepatocytes generated during chemicalinduced hyperplasia were protected from apoptosis during liver regression. In conclusion, risk assessment of chemical agents should focus on control of early cell proliferation in vivo-, this present short-term test is available for this purpose.
The San Francisco office of the Natural Resources Defense Council, a national nonprofit public interest organization, seeks a senior scientist with a Ph.D. or M.D. and relevant work experience to promote the prevention of adverse health effects from exposure to toxic chemicals. We will also consider an individual with a Masters Degree and highly relevant work experience.
The position involves bringing scientific analyses and knowledge to advocacy in various forums. Candidates should have expertise in cutting-edge toxics issues, such as the special vulnerability of children or other disproportionately exposed subpopulations to some toxics, endocrine disruption, or other noncancer endpoints. The ability to keep abreast of scientific advances, to translate technical issues into simple lay language, and to conduct outreach to persons affected by toxics as well as the scientific and medical communities is required. Salary is commensurate with experience. 
